Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 20-135




ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.


  • Cancer
  • Melanoma
  • Solid Tumor
  • Squamous Cell Carcinoma of Head and Neck
  • Breast Cancer
  • Advanced Solid Tumor


  • ONCR-177
  • pembrolizumab


Phase 1

Study Type


Further Study Details

Primary Outcome:

  • Percentage of Subjects with Dose-Limiting Toxicities (DLTs) During the First 28 Days of Treatment
  • Percentage of Subjects with Adverse Events and Serious Adverse Events

Secondary Outcome:

  • Objective Response Rate (ORR), based on RECIST v1.1, as well as Durable Response Rate (DRR) (continuous CR or PR ≥6 months), Progression Free Survival (PFS), and Overall Survival (OS)
  • Incidence of ONCR-177 detection
  • Changes in the level of anti-HSV-1 antibodies compared to baseline



Study Start Date

May 20, 2020


  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No


Oncorus, Inc.


Oncorus, Inc.

Official title

A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors Identifier



Source: Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.